Chemotherapy-induced neuropathy.
Peripheral neuropathy is a common dose-limiting toxicity of chemotherapy. Chemotherapy-induced peripheral neuropathy (CIPN) causes numerous debilitating symptoms, impairs functional capacity, and results in dose reductions or possible cessation of chemotherapy. Analgesic or neurotropic agents are only modestly effective in treating neuropathic symptoms. Animal and human studies into the pathogenesis of CIPN have demonstrated heterogeneity in the mechanism(s) of nerve injury caused by individual agents, which may partly explain the wide variation in the resultant symptoms. Development of optimal therapeutic measures to treat CIPN requires continued research into the pathophysiologic basis of nerve injury, identification of risk factors for individual patients, development of reproducible and easy-to-use measurement scales, and finally, the performance of appropriately designed clinical trials to evaluate potentially promising agents.
Bhagra
Anjali
A
Department of Oncology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Rao
Ravi D
RD
D000700:Analgesics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002491:Central Nervous System Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D017671:Platinum Compounds / Q000009:adverse effects; D012307:Risk Factors; D014748:Vinca Alkaloids / Q000009:adverse effects
D000700:Analgesics; D000970:Antineoplastic Agents; D002491:Central Nervous System Agents; D017671:Platinum Compounds; D014748:Vinca Alkaloids